SXTP — 60 Degrees Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareMicro Cap
- $3.16m
- $11.77m
- $1.41m
Brief: Sixty Degrees Pharmaceuticals Announces Patent License Agreement To Advance Development Of Tafenoquine
60 Degrees rises as FDA green lights Australian import of anti-malaria drug
Brief: 60 Degrees Pharmaceuticals Enrolls First Patient In Tafenoquine Expanded Access Clinical Study
Brief: 60 Degrees Pharmaceuticals Posts Q3 Loss of 93 cents
Brief: 60 Degrees Pharmaceuticals Announces $4 Mln Private Placement
Brief: 60 Degrees Pharmaceuticals Posts Qtrly Loss Per Share $4.23
Brief: 60 Degrees Pharma Provides University Of Kentucky With Right Of Reference To Arakoda® NDA In Support Of Sj733 Phase 2b Study
Brief: 60 Degrees Pharma Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study
Brief: 60 Degrees Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $15 Million - SEC Filing
Brief: 60 Degrees Pharma Announces IRB Approval Of Clinical Study Of Tafenoquine For Treatment Of Babesiosis
Brief: First Patient Enrolled In 60 Degrees Pharmaceuticals Clinical Trial Of Tafenoquine For Babesiosis At Tufts Medical Center First And Only Study Of Its Kind
Brief: 60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation For Acute Babesiosis Treatment
Brief: 60 Degrees Pharmaceuticals Outlines Upcoming Trial Of Tafenoquine In Babesiosis
Brief: 60 Degrees Pharmaceuticals Receives FDA Comments On Tafenoquine-Babesiosis Clinical Trial Protocol
Brief: 60 Degrees Pharmaceuticals To Sponsor Pilot Study Of Tafenoquine For Treatment Of Canine Babesiosis
Brief: 60 Degrees Pharmaceuticals To Sponsor Pre-Clinical Studies Of Tafenoquine Use In Candida Spp, Including Candida Auris
Brief: 60 Degrees Pharma Announces IRB Approval Of Phase IIA Study To Evaluate Tafenoquine For Babesiosis, Type C Meeting Re-Scheduled By FDA To January 17 2024
Brief: 60 Degrees Pharma Announces Type C Meeting With FDA To Discuss Development Of Tafenoquine For Babesiosis, An Emerging Tick-Borne Disease
Brief: 60 Degrees Pharmaceuticals Suspends Phase Iib Study Of Tafenoquine For Covid-19